7 Hills Pharma receives a $3 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the first vaccine for Chagas disease. This innovative vaccine combination with 7HP349 aims to protect millions from the Trypanosoma cruzi parasite and prevent severe outcomes of the disease.

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.